Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains
Christine Rohde,
Grégory Resch,
Jean-Paul Pirnay,
Bob G. Blasdel,
Laurent Debarbieux,
Daniel Gelman,
Andrzej Górski,
Ronen Hazan,
Isabelle Huys,
Elene Kakabadze,
Małgorzata Łobocka,
Alice Maestri,
Gabriel Magno de Freitas Almeida,
Khatuna Makalatia,
Danish J. Malik,
Ivana Mašlaňová,
Maia Merabishvili,
Roman Pantucek,
Thomas Rose,
Dana Štveráková,
Hilde Van Raemdonck,
Gilbert Verbeken,
Nina Chanishvili
Affiliations
Christine Rohde
Department of Microorganisms, Leibniz Institute DSMZ—German Collection of Microorganisms and Cell Cultures, 38100 Braunschweig, Germany
Grégory Resch
Department of Fundamental Microbiology, University of Lausanne, 1015 Lausanne, Switzerland
Jean-Paul Pirnay
Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium
Bob G. Blasdel
Laboratory of Gene Technology, Department of Biosystems, 3000 Leuven, Belgium
Laurent Debarbieux
Department of Microbiology, Institut Pasteur, 75015 Paris, France
Daniel Gelman
Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel
Andrzej Górski
Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland
Ronen Hazan
Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem 9112001, Israel
Isabelle Huys
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium
Elene Kakabadze
Eliava Institute of Bacteriophage, Microbiology and Virology, Gotua Street 3, 0160 Tbilisi, Georgia
Małgorzata Łobocka
Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 00-901 Warsaw, Poland
Alice Maestri
University of Turin, 10124 Turin, Italy
Gabriel Magno de Freitas Almeida
Centre of Excellence in Biological Interactions, Department of Biological and Environmental Science, Nanoscience Center, University of Jyväskylä, Survontie 9C, FI-40014 Jyväskylä, Finland
Khatuna Makalatia
Eliava Institute of Bacteriophage, Microbiology and Virology, Gotua Street 3, 0160 Tbilisi, Georgia
Danish J. Malik
Chemical Engineering Department, Loughborough University, Leicestershire LE11 3TU, UK
Ivana Mašlaňová
Department of Experimental Biology, Faculty of Science, Masaryk University, 60000 Brno, Czech Republic
Maia Merabishvili
Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium
Roman Pantucek
Department of Experimental Biology, Faculty of Science, Masaryk University, 60000 Brno, Czech Republic
Thomas Rose
Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium
Dana Štveráková
Department of Experimental Biology, Faculty of Science, Masaryk University, 60000 Brno, Czech Republic
Hilde Van Raemdonck
Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium
Gilbert Verbeken
Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium
Nina Chanishvili
Eliava Institute of Bacteriophage, Microbiology and Virology, Gotua Street 3, 0160 Tbilisi, Georgia
Phage therapy is increasingly put forward as a “new” potential tool in the fight against antibiotic resistant infections. During the “Centennial Celebration of Bacteriophage Research” conference in Tbilisi, Georgia on 26–29 June 2017, an international group of phage researchers committed to elaborate an expert opinion on three contentious phage therapy related issues that are hampering clinical progress in the field of phage therapy. This paper explores and discusses bacterial phage resistance, phage training and the presence of prophages in bacterial production strains while reviewing relevant research findings and experiences. Our purpose is to inform phage therapy stakeholders such as policy makers, officials of the competent authorities for medicines, phage researchers and phage producers, and members of the pharmaceutical industry. This brief also points out potential avenues for future phage therapy research and development as it specifically addresses those overarching questions that currently call for attention whenever phages go into purification processes for application.